PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17588584-6 2008 At the end of the study, these parameters were significantly lower in the pioglitazone group as compared to the placebo group (MMP-9: 392+/-286 versus 427+/-166 ng/ml; hsCRP: 1.9+/-1.7 versus 3.1+/-2.3 ng/L; MCP-1: 413+/-115 versus 471+/-146 pg/ml; p<0.05, respectively). Pioglitazone 74-86 C-C motif chemokine ligand 2 Homo sapiens 208-213 22441004-1 2012 OBJECTIVE: To observe the effects of pioglitazone hydrochloride on urinary sediment podocalyxin and monocyte chemoattractant protein-1 (MCP-1) excretion in patients with type 2 diabetes and to explore its possible renoprotective mechanisms. Pioglitazone 37-63 C-C motif chemokine ligand 2 Homo sapiens 100-134 20371128-0 2010 Hydrochloride pioglitazone decreases urinary monocyte chemoattractant protein-1 excretion in type 2 diabetics. Pioglitazone 14-26 C-C motif chemokine ligand 2 Homo sapiens 45-79 20371128-1 2010 AIM: To observe the effects of hydrochloride pioglitazone on monocyte chemoattractant protein-1 (MCP-1) excretion in type 2 diabetics and explore its reno-protective mechanism. Pioglitazone 45-57 C-C motif chemokine ligand 2 Homo sapiens 61-95 20371128-1 2010 AIM: To observe the effects of hydrochloride pioglitazone on monocyte chemoattractant protein-1 (MCP-1) excretion in type 2 diabetics and explore its reno-protective mechanism. Pioglitazone 45-57 C-C motif chemokine ligand 2 Homo sapiens 97-102 20371128-8 2010 CONCLUSIONS: Pioglitazone can decrease urinary albumin and MCP-1 excretion in type 2 diabetics, which may partly contribute to its reno-protection by inhibiting the inflammation reaction in vivo. Pioglitazone 13-25 C-C motif chemokine ligand 2 Homo sapiens 59-64 17255125-7 2007 PPAR-gamma"s activation with 15d-PGJ2 or pioglitazone reduced basal and TNF-alpha-stimulated MCP-1 expression at mRNA and protein levels at 24 h under normoxia. Pioglitazone 41-53 C-C motif chemokine ligand 2 Homo sapiens 93-98 18584038-7 2008 Pioglitazone and troglitazone demonstrated opposing actions on microglial CCL2 production that were TLR ligand-dependent. Pioglitazone 0-12 C-C motif chemokine ligand 2 Homo sapiens 74-78 17255125-8 2007 MCP-1 reduction rates at basal mRNA and protein levels were slightly but significantly lower during hypoxia than normoxia (9 vs 69% and 36 vs 42%, respectively, for 15d-PGJ2, and 0 vs 34% and 12 vs 21%, respectively, for pioglitazone). Pioglitazone 221-233 C-C motif chemokine ligand 2 Homo sapiens 0-5 25897968-10 2015 Further, rosiglitazone and pioglitazone treatment reduced serum hsCRP and MCP-1 but had no marked effects on MMP-9, IL-6 and ICAM-1. Pioglitazone 27-39 C-C motif chemokine ligand 2 Homo sapiens 74-79 16046295-0 2005 Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Pioglitazone 178-190 C-C motif chemokine ligand 2 Homo sapiens 23-59 16046295-7 2005 Pioglitazone increased S(I) by 60% and in the same subjects reduced both CD68 and MCP-1 mRNAs by >50%. Pioglitazone 0-12 C-C motif chemokine ligand 2 Homo sapiens 82-87 16046295-10 2005 Thus, treatment with pioglitazone reduces expression of CD68 and MCP-1 in adipose tissue, apparently by reducing macrophage numbers, resulting in reduced inflammatory cytokine production and improvement in S(I). Pioglitazone 21-33 C-C motif chemokine ligand 2 Homo sapiens 65-70 12411463-6 2002 Pioglitazone did not reduce local expression of MCP-1 but markedly attenuated increased expression of the MCP-1 receptor C-C chemokine receptor 2 (CCR2) in lesional and circulating monocytes. Pioglitazone 0-12 C-C motif chemokine ligand 2 Homo sapiens 106-111 28867378-9 2017 Both ROS and PGZ significantly induced the release of adiponectin and inhibited release of MCP-1 from the fat. Pioglitazone 13-16 C-C motif chemokine ligand 2 Homo sapiens 91-96